MedTrace Logo

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

NCT00054574 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-08-03

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase II trial to study the effectiveness of ABX-EGF in treating patients who have prostate cancer that has not responded to hormone therapy.

Conditions

Interventions

BIOLOGICAL

panitumumab

Sponsors & Collaborators

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Arie Belldegrun, MD, FACS · Jonsson Comprehensive Cancer Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2003-09-30
Completion
2004-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00054574 on ClinicalTrials.gov